ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cerevel surges on positive data for CVL-231 in schizophrenia trial, start of public offering
June 30, 2021Shares in Cerevel Therapeutics jumped as much as 136% Tuesday after the company reported "clinically meaningful and statistically significant" Phase Ib study results for CVL-231, a muscarinic M4-selective positive allosteric modulator . -
Novel shows promise in Phase II schizophrenia trial
February 26, 2021KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies. -
Lundbeck craters as resistant schizophrenia drug fails phase III
December 19, 2018Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.....
Pharma Sources Insight January 2025
